尔康制药12月29日获融资买入1391.12万元，融资余额2.77亿元

Group 1 - The core viewpoint of the news is that Erkang Pharmaceutical has shown significant financial performance with a notable increase in revenue and net profit, while also experiencing fluctuations in stock trading activity [2][3] Group 2 - As of December 29, Erkang Pharmaceutical's stock price decreased by 2.53%, with a trading volume of 120 million yuan [1] - The financing buy-in amount on December 29 was 13.91 million yuan, while the financing repayment was 12.54 million yuan, resulting in a net financing buy of 1.37 million yuan [1] - The total financing and securities balance for Erkang Pharmaceutical reached 277 million yuan, accounting for 3.86% of its circulating market value, which is above the 80th percentile level over the past year [1] Group 3 - As of September 30, the number of shareholders for Erkang Pharmaceutical was 49,100, an increase of 14.88% compared to the previous period [2] - The average circulating shares per person decreased by 12.95% to 28,966 shares [2] - For the period from January to September 2025, Erkang Pharmaceutical achieved an operating income of 1.006 billion yuan, representing a year-on-year growth of 17.81% [2] Group 4 - The cumulative cash distribution since the A-share listing of Erkang Pharmaceutical amounts to 540 million yuan, with 61.88 million yuan distributed over the past three years [3] - As of September 30, 2025, Hong Kong Central Clearing Limited was the fifth largest circulating shareholder, holding 25.88 million shares, an increase of 4.32 million shares from the previous period [3]